PASSAGE BIO, INC. Variable Lease, Cost
PASSAGE BIO, INC. (PASG) reported Variable Lease, Cost of $178.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-09-03
- PASSAGE BIO, INC. variable lease, cost for the quarter ending 2026-06-30 was $178.00K, a 67.22% decline year-over-year.
- PASSAGE BIO, INC. variable lease, cost for the quarter ending 2026-03-31 was $326.00K, a 39.41% decline year-over-year.
- PASSAGE BIO, INC. variable lease, cost for the quarter ending 2025-12-31 was $519.00K, a 7.45% increase year-over-year.
- PASSAGE BIO, INC. variable lease, cost for the quarter ending 2025-09-30 was $503.00K, a 5.09% decline year-over-year.
- PASSAGE BIO, INC. variable lease, cost for fiscal 2023 was $2.05M, a 14.63% increase from fiscal 2022.
- PASSAGE BIO, INC. variable lease, cost for fiscal 2022 was $1.79M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $178.00K S-4/A · filed 2026-09-03 | $504.00K S-4/A · filed 2026-09-03 | $1.02M derived: sum of 3 quarters · filed 2026-09-03 | $1.53M derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | $326.00K S-4 · filed 2026-07-21 | $845.00K derived: sum of 2 quarters · filed 2026-09-03 | $1.35M derived: sum of 3 quarters · filed 2026-09-03 | $1.89M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | $519.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $1.02M derived: sum of 2 quarters · filed 2026-09-03 | $1.56M derived: sum of 3 quarters · filed 2026-09-03 | $2.10M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $503.00K 10-Q · filed 2025-11-10 | $1.05M derived: sum of 2 quarters · filed 2026-09-03 | $1.58M 10-Q · filed 2025-11-10 | $2.07M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $543.00K S-4/A · filed 2026-09-03 | $1.08M S-4/A · filed 2026-09-03 | $1.56M derived: sum of 3 quarters · filed 2026-09-03 | $2.09M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | $538.00K S-4 · filed 2026-07-21 | $1.02M derived: sum of 2 quarters · filed 2026-09-03 | $1.55M derived: sum of 3 quarters · filed 2026-09-03 | $1.95M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | $483.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $1.01M derived: sum of 2 quarters · filed 2026-09-03 | $1.41M derived: sum of 3 quarters · filed 2026-09-03 | $2.13M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $530.00K 10-Q · filed 2025-11-10 | $924.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.64M 10-Q · filed 2025-11-10 | $2.13M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $394.00K 10-Q · filed 2025-08-12 | $1.11M 10-Q · filed 2025-08-12 | $1.60M derived: sum of 3 quarters · filed 2025-08-12 | $2.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $720.00K 10-Q · filed 2025-05-13 | $1.20M derived: sum of 2 quarters · filed 2025-05-13 | $1.85M derived: sum of 3 quarters · filed 2025-05-13 | $2.29M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.13M derived: sum of 2 quarters · filed 2025-03-04 | $1.57M derived: sum of 3 quarters · filed 2025-03-04 | $2.05M 10-K · filed 2025-03-04 |
| 2023-09-30 | $644.00K 10-Q · filed 2024-11-13 | $1.09M derived: sum of 2 quarters · filed 2024-11-13 | $1.57M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $448.00K 10-Q · filed 2024-08-08 | $926.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $478.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $1.79M 10-K · filed 2024-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |